Two Sigma Investments LP Has $3.22 Million Stake in Verve Therapeutics, Inc. (NASDAQ:VERV)

Two Sigma Investments LP increased its stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 32.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 570,304 shares of the company's stock after acquiring an additional 140,030 shares during the quarter. Two Sigma Investments LP owned approximately 0.67% of Verve Therapeutics worth $3,217,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of VERV. Tema Etfs LLC purchased a new stake in shares of Verve Therapeutics during the fourth quarter worth approximately $503,000. Point72 Asset Management L.P. acquired a new position in shares of Verve Therapeutics during the 4th quarter worth approximately $7,863,000. ProShare Advisors LLC lifted its stake in shares of Verve Therapeutics by 30.4% during the fourth quarter. ProShare Advisors LLC now owns 24,016 shares of the company's stock valued at $135,000 after buying an additional 5,592 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Verve Therapeutics by 16.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 144,749 shares of the company's stock worth $816,000 after buying an additional 20,483 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its stake in shares of Verve Therapeutics by 18.5% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company's stock valued at $10,423,000 after buying an additional 288,678 shares during the period. 97.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on VERV shares. Guggenheim lifted their price objective on Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. Wall Street Zen upgraded shares of Verve Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Royal Bank of Canada cut their price objective on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Cantor Fitzgerald upgraded Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th. Finally, William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, Verve Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $25.75.

Verve Therapeutics Trading Up 0.8%

Shares of Verve Therapeutics stock traded up $0.04 during trading on Tuesday, reaching $4.84. The company's stock had a trading volume of 273,173 shares, compared to its average volume of 1,894,403. The stock has a 50-day moving average price of $4.47 and a two-hundred day moving average price of $5.74. The stock has a market capitalization of $431.45 million, a P/E ratio of -1.97 and a beta of 1.82. Verve Therapeutics, Inc. has a one year low of $2.86 and a one year high of $9.31.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.36. The firm had revenue of $32.98 million for the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. As a group, sell-side analysts anticipate that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.